Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
Air Pollution May Increase the Risk of RA & RA-Associated ILD
Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.
Positive Week 12 Results for Rosnilimab in Patients with RA
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
Metabolic Syndrome & RA Treatment Response
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Sunrise, Sunset: A Look Back on the Year in Rheumatology
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
Advancements in Imaging
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
Can an App Reduce the Need for In-Person Visits?
Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of a Difficult-to-Treat Disease
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
What’s New in RA Research?
Dr. Aletaha discussed several studies of interventions in pre-RA, including SAVE, STIVEA, PROMPT, PRAIRI, TREAT EARLIER and STOP-RA.
All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis
EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…
- 1
- 2
- 3
- …
- 30
- Next Page »